Single Cell Analysis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Single Cell Analysis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Single Cell Analysis Market is projected to register a CAGR of 13.10% during the forecast period (2022-2027).

The employment of single-cell analysis in the study of SARS-CoV2 viral infection is gaining importance during the COVID-19 pandemic, which is expected to significantly impact the studied market growth. According to the research article published in the American Journal of Physiology-Lung Cellular and Molecular Physiology, 2021, single-cell analysis through mass cytometry by time-of-flight (CyTOF) was used to study the changes in the peripheral blood mononuclear of COVID-19-infected patients. The application of a high throughput single-cell analysis technique helps in the evaluation of the immunological responses in COVID-19 patients. Additionally, as per the research study published in Cell, 2021, single-cell RNA sequencing was applied on 284 samples of COVID-19-infected patients and created an immune landscape with 1.46 million cells, which enabled the evaluation and correlation among different immune subtype changes with varied clinical features, such as age, sex, severity, and disease stages of COVID-19. Thus, given the ongoing research activities, by exploring the application of the single-cell analysis technique in the SARS-CoV2 virus study, the studied market is expected to have good opportunities for growth during the pandemic era.

The growth of the single-cell analysis market is attributed to the technological advancements in single-cell analysis products, increasing investments in cancer research, and growing biotechnology and biopharmaceutical industries in recent years.

Cancer is one of the main reasons of death across the world. The disease has witnessed significant growth in the past years, and it is expected to rise rapidly over the forecast period. As per the World Health Organization (WHO), key facts were updated in February 2022, Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Each year, about 400 000 children develop cancer. The most common cancers vary between countries. Thus, the increasing incidence of cancer across the world rise the diagnosis rate and the demand for advanced diagnoses thereby accelerating the market. Additionally, according to International Agency for Research on Cancer (IARC), by 2040, the global burden of cancers is expected to grow to 27.5 million new cancer cases and 16.3 million deaths worldwide. Circulating tumor cells are also gaining increasing clinical attention since they are likely to enable the monitoring of cancer progression and adjustment of treatment. The single-cell sequencing analysis has found its diagnostic and prognostic biomarkers.

Additionally, in clinical diagnostics, single-cell analysis is expected to standardize and automate workflows with valuable information for real-time monitoring of cancer and eventually new therapeutic strategies for the benefit of patients. This aspect is expected to lead to more efficient and better analysis. Therefore, increasing investments in cancer research is considered one of the major driving factors for the market over the forecast period.

However, the high cost of the single-cell analysis instruments is expected to restrain the studied market growth.

Key Market TrendsThe Research Applications Segment is Expected to Grow at a Good Rate Over the Forecast Period

The research applications segment is expected to hold the maximum share, owing to the high prevalence of cancer, the increasing need for stem cell research, the initiatives for early detection of chronic diseases, and increasing awareness regarding commercially available cancer diagnostics and precision medicine. In the research segment, cancer and immunology are of growing interest among the scientific communities. In January 2022, Amgen entered into a partnership with Generate Biomedicines to discover and create protein therapeutics for five targets across several therapeutic areas and multiple modalities with an early investment of USD 1.9 billion-plus. In December 2021, Canopy Biosciences, a Bruker Company, launched assay kits for ChipCytometry. The Canopy assay kits will be used to quantitatively image dozens of targeted protein biomarkers simultaneously on a single tissue section at a single-cell spatial resolution which will streamline the user experience with ChipCytometry for a shorter pathway to meaningful biological advances. As per clinicaltrials.gov, as of March 2021, there were nearly 23,358 active, ongoing clinical trials in the area of oncology. This specifies the high rate of cancer research being conducted globally, and as the cellular, metabolic and genetic study and evaluation of tumor cells play a vital role in the understanding of various cancers, which in turn leads to the development of effective diagnostics, therapeutics, and treatment options for cancer, the use of single-cell analysis in research application is predicted to witness significant growth.

Furthermore, immunological studies aid in the early detection of therapeutic complications, including many cancer and hematology-based indications, thereby increasing the efficiency of the treatment. According to article in Journal of Immunology Research, 2020, single-cell RNA sequencing and analysis help in studying the immune response to various infections, which can lead to the development of effective vaccines against causal organisms. Furthermore, invasion of the metabolic activities of single cells is increasing the adoption of its analytical tools, thus propelling the growth of the research segment.

The North American Region Holds the Largest Market Share of the Single Cell Analysis Market, and it is Anticipated to Follow Trend the Same Over the Forecast Period

The large share of the North American single-cell analysis market is attributed to factors such as increasing collaborations among prominent players, technological advancements and growing biotechnology and pharmaceutical industries. In recent years, several government initiatives have been launched that are supplementing the growth of the single-cell analysis market in the region. For instance, in March 2022, Biognosys launched an expanded suite of proteomics platforms that provide pharmaceutical and diagnostics customers with deep biological insights across the entire R&D pipeline, from early-stage discovery to clinical settings. Similarly, in January 2022, Amgen entered into a partnership with Generate Biomedicines to discover and create protein therapeutics for five targets across several therapeutic areas and multiple modalities with an early investment of USD 1.9 billion-plus.

Additionally, the high incidence of chronic diseases such s cancers in the region is driving the market growth. According to the Globocan 2020 report, an estimated 2,281,658 new cancer cases were diagnosed in the United States in 2020, with nearly 612,390 deaths. In 2020, The most common cancers were breast (253,465), lung (227,875), prostate (209,512), and colon (101,809) in the United States.

Also, the existence of major players in the region and new product launches is expected to boost the single-cell analysis market. For instance, in March 2021The United States Food and Drug Administration approved Abecma (idecabtagene vicleucel), to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines of therapy. Abecma is the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma. Thus, owing to the above-mentioned factors, the single-cell analysis market is expected to witness significant growth over the forecast period in North America.

Competitive Landscape

The single-cell analysis market has several major players. The major players in the studied market comprise Illumina Inc., Agilent Technologies Inc., Bio-Rad Laboratories Inc., Becton, Dickinson and Company, Beckman Coulter Inc. (Danaher Corporation), and Fluidigm Corporation. The companies are implementing certain strategic initiatives, such as mergers, new product launches, acquisitions, and partnerships that help them in strengthening their market position. For instance, in April 2020, Bio-Rad Laboratories Inc. completed the acquisition of Celsee Inc., which is a single-cell analysis solution provider, thereby expanding its product portfolio of precision medicine and single-cell analysis.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.